Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: In vivo identification from hypoxic tumor cells

Mamoru Uemura, Hirofumi Yamamoto, Ichiro Takemasa, Koshi Mimori, Hideyuki Hemmi, Tsunekazu Mizushima, Masataka Ikeda, Mitsugu Sekimoto, Nariaki Matsuura, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Purpose: This study aimed to identify novel hypoxia-inducible and prognostic markers in vivo from hypoxic tumor cells. Experimental Design: Using carbonic anhydrase 9 and CD34 as a guide for hypoxic tumor cells, laser capture microdissection was used to isolate colorectal cancer (CRC) liver metastases. The samples were analyzed by microarray analysis, in parallel with five CRC cell lines cultured under hypoxic conditions. To evaluate the prognostic impact of the expression of certain genes, samples from a total of 356 CRC patients were analyzed by microarray or quantitative reverse transcription-PCR. In vitro mechanistic studies and in vivo therapeutic experiments were also done about a histone H3 Lys9 demethylase, Jumonji domain containing 1A (JMJD1A). Results: Several candidate genes were identified by microarray analysis of liver metastases and culturing of CRC cells under hypoxic conditions. Among them, we found that JMJD1A was a novel independent prognostic factor for CRC (P = 0.013). In vitro assays revealed that loss of JMJD1A by small interfering RNA treatment was associated with a reduction of proliferative activity and decrease in invasion of CRC cell lines. Furthermore, treatment with an adenovirus system for antisense JMJD1A construct displayed prominent therapeutic effects when injected into established tumor xenografts of the CRC cell lines HCT116 and DLD1. Conclusions: JMJD1A is a useful biomarker for hypoxic tumor cells and a prognostic marker that could be a promising therapeutic target against CRC.

Original languageEnglish
Pages (from-to)4636-4646
Number of pages11
JournalClinical Cancer Research
Volume16
Issue number18
DOIs
Publication statusPublished - Sep 15 2010

Fingerprint

Colorectal Neoplasms
Neoplasms
Microarray Analysis
Cell Line
Neoplasm Metastasis
Laser Capture Microdissection
Therapeutic Uses
Therapeutics
Liver Neoplasms
Tumor Biomarkers
Heterografts
Adenoviridae
Histones
Small Interfering RNA
Reverse Transcription
Research Design
Gene Expression
Polymerase Chain Reaction
Liver
Genes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer : In vivo identification from hypoxic tumor cells. / Uemura, Mamoru; Yamamoto, Hirofumi; Takemasa, Ichiro; Mimori, Koshi; Hemmi, Hideyuki; Mizushima, Tsunekazu; Ikeda, Masataka; Sekimoto, Mitsugu; Matsuura, Nariaki; Doki, Yuichiro; Mori, Masaki.

In: Clinical Cancer Research, Vol. 16, No. 18, 15.09.2010, p. 4636-4646.

Research output: Contribution to journalArticle

Uemura, M, Yamamoto, H, Takemasa, I, Mimori, K, Hemmi, H, Mizushima, T, Ikeda, M, Sekimoto, M, Matsuura, N, Doki, Y & Mori, M 2010, 'Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: In vivo identification from hypoxic tumor cells', Clinical Cancer Research, vol. 16, no. 18, pp. 4636-4646. https://doi.org/10.1158/1078-0432.CCR-10-0407
Uemura, Mamoru ; Yamamoto, Hirofumi ; Takemasa, Ichiro ; Mimori, Koshi ; Hemmi, Hideyuki ; Mizushima, Tsunekazu ; Ikeda, Masataka ; Sekimoto, Mitsugu ; Matsuura, Nariaki ; Doki, Yuichiro ; Mori, Masaki. / Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer : In vivo identification from hypoxic tumor cells. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 18. pp. 4636-4646.
@article{e82a9d4d876548138450d56408b1a24f,
title = "Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: In vivo identification from hypoxic tumor cells",
abstract = "Purpose: This study aimed to identify novel hypoxia-inducible and prognostic markers in vivo from hypoxic tumor cells. Experimental Design: Using carbonic anhydrase 9 and CD34 as a guide for hypoxic tumor cells, laser capture microdissection was used to isolate colorectal cancer (CRC) liver metastases. The samples were analyzed by microarray analysis, in parallel with five CRC cell lines cultured under hypoxic conditions. To evaluate the prognostic impact of the expression of certain genes, samples from a total of 356 CRC patients were analyzed by microarray or quantitative reverse transcription-PCR. In vitro mechanistic studies and in vivo therapeutic experiments were also done about a histone H3 Lys9 demethylase, Jumonji domain containing 1A (JMJD1A). Results: Several candidate genes were identified by microarray analysis of liver metastases and culturing of CRC cells under hypoxic conditions. Among them, we found that JMJD1A was a novel independent prognostic factor for CRC (P = 0.013). In vitro assays revealed that loss of JMJD1A by small interfering RNA treatment was associated with a reduction of proliferative activity and decrease in invasion of CRC cell lines. Furthermore, treatment with an adenovirus system for antisense JMJD1A construct displayed prominent therapeutic effects when injected into established tumor xenografts of the CRC cell lines HCT116 and DLD1. Conclusions: JMJD1A is a useful biomarker for hypoxic tumor cells and a prognostic marker that could be a promising therapeutic target against CRC.",
author = "Mamoru Uemura and Hirofumi Yamamoto and Ichiro Takemasa and Koshi Mimori and Hideyuki Hemmi and Tsunekazu Mizushima and Masataka Ikeda and Mitsugu Sekimoto and Nariaki Matsuura and Yuichiro Doki and Masaki Mori",
year = "2010",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-10-0407",
language = "English",
volume = "16",
pages = "4636--4646",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer

T2 - In vivo identification from hypoxic tumor cells

AU - Uemura, Mamoru

AU - Yamamoto, Hirofumi

AU - Takemasa, Ichiro

AU - Mimori, Koshi

AU - Hemmi, Hideyuki

AU - Mizushima, Tsunekazu

AU - Ikeda, Masataka

AU - Sekimoto, Mitsugu

AU - Matsuura, Nariaki

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2010/9/15

Y1 - 2010/9/15

N2 - Purpose: This study aimed to identify novel hypoxia-inducible and prognostic markers in vivo from hypoxic tumor cells. Experimental Design: Using carbonic anhydrase 9 and CD34 as a guide for hypoxic tumor cells, laser capture microdissection was used to isolate colorectal cancer (CRC) liver metastases. The samples were analyzed by microarray analysis, in parallel with five CRC cell lines cultured under hypoxic conditions. To evaluate the prognostic impact of the expression of certain genes, samples from a total of 356 CRC patients were analyzed by microarray or quantitative reverse transcription-PCR. In vitro mechanistic studies and in vivo therapeutic experiments were also done about a histone H3 Lys9 demethylase, Jumonji domain containing 1A (JMJD1A). Results: Several candidate genes were identified by microarray analysis of liver metastases and culturing of CRC cells under hypoxic conditions. Among them, we found that JMJD1A was a novel independent prognostic factor for CRC (P = 0.013). In vitro assays revealed that loss of JMJD1A by small interfering RNA treatment was associated with a reduction of proliferative activity and decrease in invasion of CRC cell lines. Furthermore, treatment with an adenovirus system for antisense JMJD1A construct displayed prominent therapeutic effects when injected into established tumor xenografts of the CRC cell lines HCT116 and DLD1. Conclusions: JMJD1A is a useful biomarker for hypoxic tumor cells and a prognostic marker that could be a promising therapeutic target against CRC.

AB - Purpose: This study aimed to identify novel hypoxia-inducible and prognostic markers in vivo from hypoxic tumor cells. Experimental Design: Using carbonic anhydrase 9 and CD34 as a guide for hypoxic tumor cells, laser capture microdissection was used to isolate colorectal cancer (CRC) liver metastases. The samples were analyzed by microarray analysis, in parallel with five CRC cell lines cultured under hypoxic conditions. To evaluate the prognostic impact of the expression of certain genes, samples from a total of 356 CRC patients were analyzed by microarray or quantitative reverse transcription-PCR. In vitro mechanistic studies and in vivo therapeutic experiments were also done about a histone H3 Lys9 demethylase, Jumonji domain containing 1A (JMJD1A). Results: Several candidate genes were identified by microarray analysis of liver metastases and culturing of CRC cells under hypoxic conditions. Among them, we found that JMJD1A was a novel independent prognostic factor for CRC (P = 0.013). In vitro assays revealed that loss of JMJD1A by small interfering RNA treatment was associated with a reduction of proliferative activity and decrease in invasion of CRC cell lines. Furthermore, treatment with an adenovirus system for antisense JMJD1A construct displayed prominent therapeutic effects when injected into established tumor xenografts of the CRC cell lines HCT116 and DLD1. Conclusions: JMJD1A is a useful biomarker for hypoxic tumor cells and a prognostic marker that could be a promising therapeutic target against CRC.

UR - http://www.scopus.com/inward/record.url?scp=77956692764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956692764&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-0407

DO - 10.1158/1078-0432.CCR-10-0407

M3 - Article

C2 - 20823141

AN - SCOPUS:77956692764

VL - 16

SP - 4636

EP - 4646

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -